Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company developing novel small molecules for the treatment of inflammatory diseases, including treatments for asthma, allergies, and arthritis, and also has the rights to a patented small molecule with anti-tumor activity.
IZP's Institutional investors include Royal Bank, Royal Trust, Biotech Investments Ltd., Goldman Sachs, Business Development Bank of Canada, Sofinov, and Working Opportunity Fund.
For more information visit: inflazyme.com
An interview with CEO Ian McBeath: twst.com
Vegetables, animals, and millionaires: canbus.com |
